Pulse Biosciences, Inc.
NCM: PLSELive Quote
📈 ZcoreAI Score
Our AI model analyzes Pulse Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PLSE Z-Score →About Pulse Biosciences, Inc.
Healthcare
Medical Instruments & Supplies
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
📊 Fundamental Analysis
Pulse Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -74.4%, which indicates that capital utilization is currently under pressure.
At a current price of $18.67, PLSE currently sits at the 44th percentile of its 52-week range (Range: $12.56 - $26.30).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.27B
Trailing P/E
--
Forward P/E
-21.71
Beta (5Y)
1.69
52W High
$26.30
52W Low
$12.56
Avg Volume
350K
Day High
Day Low